Key clinical point: CAR T-cell therapy was effective for gastrointestinal relapsed/refractory B-cell lymphoma.
Major finding: An objective response was achieved in 10/14 patients, with 7 achieving a complete response.
Study details: Open-label, single-center study of infusion of anti-CD22 and anti-CD19 CAR T cells in 14 patients with r/r B-cell malignancies involving the GI tract.
Disclosures: The study was funded by the National Science Foundation of China. The authors reported they had no conflicts of interest.
Zheng C et al. Cytotherapy. 2020;22:166-71.